Medistep Healthcare IPO GMP

August 18, 2025 Written By Mihir Gohel, Reviewed and Fact Checked by Harpal Parmar

The Medistep Healthcare IPO is an SME fixed price issue of ₹16.10 crore, opening in 8 August 2025 on the NSE EMERGE platform. Based in Ahmedabad, the company operates in the healthcare personal care sector, manufacturing sanitary pads, energy powders, and trading a diverse range of pharmaceutical products. The IPO proceeds are aimed at supporting capacity expansion and enhancing operational efficiencies. With a focus on quality and innovation, Medistep Healthcare targets growing demand in healthcare and personal care segments. The Medistep Healthcare IPO offers investors a chance to participate in a promising, emerging player within India’s expanding healthcare and personal care industry.

₹10

Latest IPO GMP

Last updated on 17 Aug 2025 12.31

₹43

IPO Offer Price

*cut off price

₹53.00

Listing Price

Listing Date 18/08/2025

Expert Opinions

The Medistep Healthcare IPO is attracting moderate market interest, reflecting cautious optimism about its niche presence in pharmaceutical and healthcare product manufacturing. The company’s strengths include a diversified product portfolio encompassing sanitary pads, energy powders, pharmaceutical, nutraceutical, intimate, and surgical products. For FY 2025, Medistep Healthcare demonstrated strong financial health with a Return on Equity (ROE) of 29.06%, Return on Capital Employed (ROCE) of 38.91%, and an EBITDA margin of 11.27%, showcasing effective cost management and profitability.

Risks include industry competition, regulatory compliance challenges, and dependence on raw material availability. From a long-term investment viewpoint, Medistep Healthcare offers growth potential by expanding manufacturing capacity and market reach. The Medistep Healthcare IPO is suitable for investors seeking exposure to India’s growing healthcare and personal care product sectors.

Investor Considerations

The Medistep Healthcare IPO reflects a company with steady growth and solid fundamentals. The firm’s revenue increased from ₹27.65 crore in FY 2023 to ₹31.62 crore in FY 2025, with a PAT margin of 8.35%, indicating improving profitability. The healthcare and personal care sector has a positive outlook due to rising awareness of hygiene and wellness products. The IPO valuation includes a Price to Book Value of 2.67 and a Return on Net Worth (RoNW) of 29.06%, showing efficient capital use.

Growth prospects are driven by capacity expansion and product diversification. Risk factors include regulatory challenges, raw material price fluctuations, and competition. Investors with a long-term horizon may find Medistep Healthcare IPO attractive for exposure to a dynamic healthcare segment, while short-term investors should consider the SME listing’s liquidity and volatility.